Piperazine derivatives
US5369103A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 19, 1992 |
| Grant date | Nov 29, 1994 |
| Priority date | — |
| Expiry date | Jun 19, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D213/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
##STR1## where A is an alkylene chain of 1 or 2 carbon atoms optionally substituted by one or more lower alkyl groups, R is hydrogen or lower alkyl, R.sup.1 is a mono or bicyclic aryl or a heteroaryl radical, R.sup.2 is an aryl radical, a heteroaryl radical, or an aryl-or heteroaryl-lower alkyl radical, R.sup.3 is hydrogen, lower alkyl or aryl and R.sup.4 is hydrogen, lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, or aryl(lower)alkyl or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom and the dotted line represents a single or double bond, the hydrogen atoms shown in brackets being present when the dotted line represents a single bond and their pharmaceutically acceptable acid addition salts are 5-HT.sub.1A binding agents which may be used, for example, for the treatment of CNS disorders such as anxiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.